Indication
Testicular germ cell tumor
A testicular germ cell tumor is a malignancy originating from the sperm-producing germ cells of the male reproductive system, representing over 90% of all primary testicular cancers. Read more about Testicular germ cell tumor
41 drugs 22 manufacturers
Drugs that treat it
Common Testicular germ cell tumor therapies.
BLEOMYCIN SULFATE
IFOSFAMIDE
IFOSFAMIDE
IFEX (ifosfamide)
CISPLATIN
CISPLATIN
IFOSFAMIDE
BLEOMYCIN (bleomycin sulfate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonA testicular germ cell tumor is a malignancy originating from the sperm-producing germ cells of the male reproductive system, representing over 90% of all primary testicular cancers.
It most commonly affects adolescent and young adult males between 15 and 35 years of age and typically manifests clinically as a painless, firm scrotal mass or swelling.
Pathophysiologically, these neoplasms are categorized into two primary histological groups: seminomas, which often exhibit slower growth and marked radiosensitivity, and nonseminomatous germ cell tumors, which encompass embryonal carcinoma, teratoma, yolk sac tumor, and choriocarcinoma.
Definitive clinical management and staging frequently involve serum tumor marker evaluation, including alpha-fetoprotein, beta-human chorionic gonadotropin, and lactate dehydrogenase.
- nih.gov
A testicular germ cell tumor is a malignancy originating from the sperm-producing germ cells of the male reproductive system, representing over 90% of all primary testicular cancers
- cancer.gov
A testicular germ cell tumor is a malignancy originating from the sperm-producing germ cells of the male reproductive system, representing over 90% of all primary testicular cancers
- mskcc.org
A testicular germ cell tumor is a malignancy originating from the sperm-producing germ cells of the male reproductive system, representing over 90% of all primary testicular cancers
- nih.gov
It most commonly affects adolescent and young adult males between 15 and 35 years of age and typically manifests clinically as a painless, firm scrotal mass or swelling
- medlineplus.gov
It most commonly affects adolescent and young adult males between 15 and 35 years of age and typically manifests clinically as a painless, firm scrotal mass or swelling
- mayoclinic.org
It most commonly affects adolescent and young adult males between 15 and 35 years of age and typically manifests clinically as a painless, firm scrotal mass or swelling
- nih.gov
It most commonly affects adolescent and young adult males between 15 and 35 years of age and typically manifests clinically as a painless, firm scrotal mass or swelling
- cancer.gov
Pathophysiologically, these neoplasms are categorized into two primary histological groups: seminomas, which often exhibit slower growth and marked radiosensitivity, and nonseminomatous germ cell tumors, which encompass embryonal carcinoma, teratoma, yolk sac tumor, and choriocarcinoma Definitive clinical management and staging frequently involve serum tumor marker evaluation, including alpha-fetoprotein, beta-human chorionic gonadotropin, and lactate dehydrogenase
- cancer.gov
Pathophysiologically, these neoplasms are categorized into two primary histological groups: seminomas, which often exhibit slower growth and marked radiosensitivity, and nonseminomatous germ cell tumors, which encompass embryonal carcinoma, teratoma, yolk sac tumor, and choriocarcinoma
- medlineplus.gov
Pathophysiologically, these neoplasms are categorized into two primary histological groups: seminomas, which often exhibit slower growth and marked radiosensitivity, and nonseminomatous germ cell tumors, which encompass embryonal carcinoma, teratoma, yolk sac tumor, and choriocarcinoma
Personalize your experience
Follow Testicular germ cell tumor and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.